$TRGM Vista Partners Initiates Coverage on Targeted Medical Pharma, Inc. (Ticker: TRGM); $2.75 Target Price
Vista Partners Initiates Coverage on Targeted Medical Pharma, Inc. (Ticker: TRGM); $2.75 Target PriceSAN FRANCISCO, CA--(Marketwired - Nov 20, 2013) - Vista Partners announced today that it has initiated coverage on Targeted Medical Pharma, Inc. (OTCQB: TRGM) ("The Company," or "TRGM"); with a twelve month target price of $2.75. Ross Silver, Principal Analyst at Vista Partners, stated, "TRGM develops and sells a line of patented prescription medical food products that are currently sold in the United States through a network of distributors and directly to physicians who dispense medical foods and other pharmaceutical products through their office practices. With recent reductions in physician reimbursements for medical services by Medicare, workers compensation and private insurance companies, many physicians are actively seeking additional sources of practice revenues." Mr. Silver concludes, "Nestlé Health Science, a subsidiary of Nestlé, has been actively acquiring medical food companies, one of which was Prometheus Laboratories, a firm specializing in diagnostics and pharmaceuticals in gastrointestinal and oncology. According to an article by Bloomberg, Nestlé may have paid 500M Swiss Francs ($550M U.S.) to 1B Swiss Francs ($1.1B U.S.) for Prometheus."To download a FREE copy of the Targeted Medical Pharma, Inc. research report, please visit http://www.vistapglobal.com and click the "download research" icon to gain access to the report. About Vista Partners:Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista focuses on investing in and providing investment considerations on publicly traded companies through a platform of stock research reports, newsletters, company specific webpages and daily commentary. The platform of products is meant to serve as potential tools for investors to learn about investment considerations. It is Vista's mission to provide investors with tools that may enable them to make profitable investment decisions with the goal to deliver investment considerations that outperform small, mid and large cap equity indexes. Please follow us on Twitter @VistaPResearch & Facebook at Vista-Partners to receive updates, thoughts and ideas about and our coverage universe of companies and more.Disclaimer & Disclosure:For a full list of disclaimers and disclosures, please visit our website www.vistapglobal.com or click here.Contact:877.215.4813Email Contact
Vista Partners Initiates Coverage on Targeted Medical Pharma, Inc. (Ticker: TRGM); $2.75 Target PriceSAN FRANCISCO, CA--(Marketwired - Nov 20, 2013) - Vista Partners announced today that it has initiated coverage on Targeted Medical Pharma, Inc. (OTCQB: TRGM) ("The Company," or "TRGM"); with a twelve month target price of $2.75. Ross Silver, Principal Analyst at Vista Partners, stated, "TRGM develops and sells a line of patented prescription medical food products that are currently sold in the United States through a network of distributors and directly to physicians who dispense medical foods and other pharmaceutical products through their office practices. With recent reductions in physician reimbursements for medical services by Medicare, workers compensation and private insurance companies, many physicians are actively seeking additional sources of practice revenues." Mr. Silver concludes, "Nestlé Health Science, a subsidiary of Nestlé, has been actively acquiring medical food companies, one of which was Prometheus Laboratories, a firm specializing in diagnostics and pharmaceuticals in gastrointestinal and oncology. According to an article by Bloomberg, Nestlé may have paid 500M Swiss Francs ($550M U.S.) to 1B Swiss Francs ($1.1B U.S.) for Prometheus."To download a FREE copy of the Targeted Medical Pharma, Inc. research report, please visit http://www.vistapglobal.com and click the "download research" icon to gain access to the report. About Vista Partners:Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista focuses on investing in and providing investment considerations on publicly traded companies through a platform of stock research reports, newsletters, company specific webpages and daily commentary. The platform of products is meant to serve as potential tools for investors to learn about investment considerations. It is Vista's mission to provide investors with tools that may enable them to make profitable investment decisions with the goal to deliver investment considerations that outperform small, mid and large cap equity indexes. Please follow us on Twitter @VistaPResearch & Facebook at Vista-Partners to receive updates, thoughts and ideas about and our coverage universe of companies and more.Disclaimer & Disclosure:For a full list of disclaimers and disclosures, please visit our website www.vistapglobal.com or click here.Contact:877.215.4813Email Contact
